Drug
RLX030
RLX030 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
3
75%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
NCT01546532
completedphase_3
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
NCT01870778
terminatedphase_2
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
NCT01566630
completedphase_2
Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
NCT01543854
Clinical Trials (4)
Showing 4 of 4 trials
NCT01546532Phase 2
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
NCT01870778Phase 3
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
NCT01566630Phase 2
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
NCT01543854Phase 2
Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4